Message #4 From:
NewsBot Date: August 4, 2006 12:53:00 PM
CYDY News CytoDyn Invited to Present at XVI World AIDS Conference
SANTA FE, N.M.--(BUSINESS WIRE)--Aug. 4, 2006--CytoDyn, Inc. (OTCBB:CYDY) has been invited to present clinical results from Cytolin(R) at the Treatment Horizons Forum of The AIDS Institute to be held on August 12, 2006 in conjunction with the XVI International AIDS Conference in Toronto. "CytoDyn will show how its targeted immune therapy reduces viral activity while avoiding the emergence of drug-resistant strains of HIV," according to Allen D. Allen, the Company's CEO. The need to continually produce new anti-microbial agents to compensate for the emergence of drug resistant strains of HIV will ultimately be limited by resources, infrastructure, and toxicity, Allen believes.
Dr. Glenn Morrison, Director of Clinical Development and Regulatory Affairs for Symbion Research International, Inc., CytoDyn's CRO, will present Phase I/II data demonstrating the antiviral effects and absence of liver toxicity in individuals who have failed Highly Active Antiretroviral Therapy (HAART) after Cytolin(R) was used to protect CD4+ T lymphocytes from the anti-self, anti-CD4 cytotoxic T lymphocytes that proliferate uniquely in humans infected with HIV. CytoDyn has been developing this targeted immune therapy since 1997. The underlying science was first published in the peer-review journals during the early 1990s.
"Millions of people around the world are desperate for the successful clinical development of a commercially available immune-based therapy for the emerging crisis of drug-resistant HIV. Cytolin(R) is one of the very few promising candidates in advance stage clinical development that shows clinical promise to address this urgent need globally," said David Miller, Board Member of the AIDS Institute and long time AIDS treatment activist. "An immune therapy that suppresses drug resistant HIV could extend the useful lives of the antiretroviral drugs that people with AIDS have been depending upon, such as recent additions to the armamentarium by Gilead (Nasdaq: GILD)," Miller added.
HIV, the virus that leads to acquired immune deficiency syndrome (AIDS), remains a global epidemic. World health officials estimate 39 million people are now infected with HIV. Some three million people died of AIDS last year, worldwide, and millions more are expected to die from AIDS this year (source www.aegis.com). With the rate of infection accelerating in many parts of the world, the search for an effective immune-based therapy for HIV is one of the highest public health priorities, according to Miller.
About CytoDyn
CytoDyn, Inc. is a company focused on developing products to treat and to prevent serious human diseases. CytoDyn, Inc. is a Colorado corporation with its home office in Santa Fe, NM. The company's shares are traded on the Over The Counter Bulletin Board under the symbol CYDY. "Cytolin" and "CytoDyn" (as used to identify a particular class of products) are the registered trademarks of CytoDyn, Inc. Our graphic logo is the registered mark of CytoDyn, Inc. For more information, including a review of the literature, please visit our web site at www.cytodyn.com.
About The AIDS Institute
The AIDS Institute (TAI) is a leading national public policy research, advocacy, and education agency with offices in Tampa, Florida and Washington, DC, and is affiliated with The Division of Infectious Diseases and Tropical Medicine at the University of South Florida's College of Medicine. Visit its web site at www.theaidsinstitute.org.
About The XVI World AIDS Conference
AIDS 2006 will be a landmark opportunity for science, government, community and leadership from around the world to advance our collective response to the epidemic. AIDS 2006 is rooted firmly in the vision that the International AIDS Conference must foster an environment of scientific inquiry, forthright dialogue, collective action, and greater accountability among all parties. The conference theme for AIDS 2006 is Time to Deliver, reminding us of past and present commitments for action on HIV/AIDS and demanding accountability for those promises at every level of the response. AIDS 2006 will be a landmark opportunity to review our collective experience with the epidemic and set an agenda for future action. For more information visit www.aids2006.org AIDS 2006 - XVI International AIDS Conference - 13-18 August 2006 - Toronto Canada.
Disclaimer
Forward looking statements are statements that are not historical facts. CytoDyn's management makes forward looking statements concerning the Company's expected future operations, performance and other developments. These forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. There can be no assurance that such risks and uncertainties, or other factors, will not affect the accuracy of such forward-looking statements. It is impossible to identify all factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, government regulation, managing and maintaining growth, victimization by white-collar offenders, and the effects of adverse publicity, litigation, competition, and other factors that may be identified from time to time in the Company's announcements.
